TCGA-GM-A2DM-01A-11R-A180-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 108
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.300
- HYPOXIA+0.280
- TNFA_SIGNALING_VIA_NFKB+0.280
- ESTROGEN_RESPONSE_EARLY+0.230
- HEME_METABOLISM+0.230
- UNFOLDED_PROTEIN_RESPONSE+0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.160
- BILE_ACID_METABOLISM+0.150
- ANDROGEN_RESPONSE+0.120
- INFLAMMATORY_RESPONSE+0.110
Top 10 suppressed
- E2F_TARGETS-0.490
- G2M_CHECKPOINT-0.490
- INTERFERON_ALPHA_RESPONSE-0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- APICAL_JUNCTION-0.310
- INTERFERON_GAMMA_RESPONSE-0.300
- WNT_BETA_CATENIN_SIGNALING-0.270
- NOTCH_SIGNALING-0.200
- KRAS_SIGNALING_DN-0.180
- APICAL_SURFACE-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-6953-01A-11R-1915-07 | — | — | 0.768 |
| 2 | SRR10842356 | — | — | 0.745 |
| 3 | SRR8518157 | — | F | 0.725 |
| 4 | TCGA-OR-A5LL-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.721 |
| 5 | SRR8518177 | — | F | 0.708 |
| 6 | TCGA-BH-A18S-01A-11R-A12D-07 | — | B | 0.696 |
| 7 | SRR8943024 | — | — | 0.694 |
| 8 | BS_9M5XJ10G | Med | Medulloblastoma | 0.690 |
| 9 | TCGA-86-8669-01A-11R-2403-07 | — | cohortA3 | 0.687 |
| 10 | TCGA-78-7163-01A-12R-2066-07 | — | cohortA1 | 0.684 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.230 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| COAGULATION | 0.040 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.040 | Inavolisib | — uncovered |